Global Markets Direct’s, ‘ChemoCentryx, Inc. – Product Pipeline Review -2015′, provides an overview of the ChemoCentryx, Inc.’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of ChemoCentryx, Inc.’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

• The report provides brief overview of ChemoCentryx, Inc. including business description, key information and facts, and its locations and subsidiaries
• The report reviews current pipeline of ChemoCentryx, Inc.’s human therapeutic division and enlists all their major and minor projects
• The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones
• Special feature on out-licensed and partnered product portfolio
• The report summarizes all the dormant and discontinued pipeline projects
• Latest company statement
• Latest news and deals relating to the ChemoCentryx, Inc.’s pipeline products

Reasons to buy

• Evaluate ChemoCentryx, Inc.’s strategic position with total access to detailed information on its product pipeline
• Assess the growth potential of ChemoCentryx, Inc. in its therapy areas of focus
• Identify new drug targets and therapeutic classes in the ChemoCentryx, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
• Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
• Develop strategic initiatives by understanding the focus areas of ChemoCentryx, Inc. and exploit collaboration and partnership opportunities
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
• Plan mergers and acquisitions effectively by identifying the most promising pipeline of ChemoCentryx, Inc.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
• Explore the dormant and discontinued projects of ChemoCentryx, Inc. and identify potential opportunities in those areas
• Avoid Intellectual Property Rights related issues

Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 5
ChemoCentryx, Inc. Snapshot 6
ChemoCentryx, Inc. Overview 6
Key Information 6
Key Facts 6
ChemoCentryx, Inc. - Research and Development Overview 7
Key Therapeutic Areas 7
ChemoCentryx, Inc. - Pipeline Review 10
Pipeline Products by Stage of Development 10
Pipeline Products - Monotherapy 11
ChemoCentryx, Inc. - Pipeline Products Glance 12
ChemoCentryx, Inc. - Late Stage Pipeline Products 12
Phase III Products/Combination Treatment Modalities 12
ChemoCentryx, Inc. - Clinical Stage Pipeline Products 13
Phase II Products/Combination Treatment Modalities 13
Phase I Products/Combination Treatment Modalities 14
ChemoCentryx, Inc. - Early Stage Pipeline Products 15
Preclinical Products/Combination Treatment Modalities 15
Discovery Products/Combination Treatment Modalities 16
ChemoCentryx, Inc. - Unknown Stage Pipeline Products 17
Unknown Products/Combination Treatment Modalities 17
ChemoCentryx, Inc. - Drug Profiles 18
vercirnon sodium 18
Product Description 18
Mechanism of Action 18
R&D Progress 18
CCX-140 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
CCX-168 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
CCX-354 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
CCX-507 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
CCX-872 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
CCX-1378 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
CCX-1641 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
CCX-6239 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
CCX-650 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
CCX-721 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
CCX-771 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
Small Molecule to Antagonize CCR1 for Undisclosed Indication 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
Small Molecule to Antagonize CCR6 for Psoriasis 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
Small Molecule to Antagonize CXCR6 for Autoimmune, Oncology and Liver Diseases 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
Small Molecules to Antagonize CCR and CXCR for Oncology and Autoimmune Disease 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
CCR2-3G 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
CCR9-3G 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
CCX-956 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
ChemoCentryx, Inc. - Pipeline Analysis 42
ChemoCentryx, Inc. - Pipeline Products by Target 42
ChemoCentryx, Inc. - Pipeline Products by Route of Administration 43
ChemoCentryx, Inc. - Pipeline Products by Molecule Type 44
ChemoCentryx, Inc. - Pipeline Products by Mechanism of Action 45
ChemoCentryx, Inc. - Recent Pipeline Updates 46
ChemoCentryx, Inc. - Dormant Projects 54
ChemoCentryx, Inc. - Discontinued Pipeline Products 55
Discontinued Pipeline Product Profiles 55
CCX-832 55
vercirnon sodium 55
ChemoCentryx, Inc. - Locations And Subsidiaries 56
Head Office 56
Appendix 57
Methodology 57
Coverage 57
Secondary Research 57
Primary Research 57
Expert Panel Validation 57
Contact Us 57
Disclaimer 58

List of Tables

ChemoCentryx, Inc., Key Information 6
ChemoCentryx, Inc., Key Facts 6
ChemoCentryx, Inc. - Pipeline by Indication, 2015 8
ChemoCentryx, Inc. - Pipeline by Stage of Development, 2015 10
ChemoCentryx, Inc. - Monotherapy Products in Pipeline, 2015 11
ChemoCentryx, Inc. - Phase III, 2015 12
ChemoCentryx, Inc. - Phase II, 2015 13
ChemoCentryx, Inc. - Phase I, 2015 14
ChemoCentryx, Inc. - Preclinical, 2015 15
ChemoCentryx, Inc. - Discovery, 2015 16
ChemoCentryx, Inc. - Unknown, 2015 17
ChemoCentryx, Inc. - Pipeline by Target, 2015 42
ChemoCentryx, Inc. - Pipeline by Route of Administration, 2015 43
ChemoCentryx, Inc. - Pipeline by Molecule Type, 2015 44
ChemoCentryx, Inc. - Pipeline Products by Mechanism of Action, 2015 45
ChemoCentryx, Inc. - Recent Pipeline Updates, 2015 46
ChemoCentryx, Inc. - Dormant Developmental Projects,2015 54
ChemoCentryx, Inc. - Discontinued Pipeline Products, 2015 55

List of Figures

ChemoCentryx, Inc. - Pipeline by Top 10 Indication, 2015 8
ChemoCentryx, Inc. - Pipeline by Stage of Development, 2015 10
ChemoCentryx, Inc. - Monotherapy Products in Pipeline, 2015 11
ChemoCentryx, Inc. - Pipeline by Top 10 Target, 2015 42
ChemoCentryx, Inc. - Pipeline by Top 10 Route of Administration, 2015 43
ChemoCentryx, Inc. - Pipeline by Top 10 Molecule Type, 2015 44
ChemoCentryx, Inc. - Pipeline Products by Top 10 Mechanism of Action, 2015 45